-
Palantir chief says France's digital sovereignty push 'backfiring'
-
NBA strips five first-round draft picks from Clippers for Leonard salary cap violations
-
US energy firms dominate Venezuela deals worth billions
-
Kane brace helps Bayern win German Cup opener
-
Iran, US trade threats after escalation in fighting
-
Migrant plight, local anger divide Ceuta one month after influx
-
US jury deadlocks again in Lindsay Clancy's child murder trial
-
Outrage as Maltese tycoon acquitted of reporter's murder
-
Lake America? No way, Canadians say
-
Rare train of Pacific cyclones fueled by historic El Nino
-
Spain report flags Moroccan police failings in Ceuta migrant rush
-
Macron, King Charles hail UK-France ties after viewing Bayeux Tapestry
-
Tech bosses press G20 to build data centers, but split on risk
-
Fury hits out at 'coward' Joshua as 'Battle of Britain' talks go on
-
Dolly Parton to get new Hollywood star after vandalism
-
Maltese tycoon acquitted of masterminding reporter's murder
-
Trump 'happy' Prince Harry and Meghan have left US
-
George Clooney: a Hollywood icon and campaigner
-
Michelson shocks Nakashima in US Open clash of rising Americans
-
Europe, US closer than they look on tech rules, says EU tech chief
-
Another body recovered after ferry capsizes off northern Cyprus: official
-
Clooney honoured as Hollywood-light Venice Film Festival kicks off
-
Cupertino Chamber President Claudio Bono Invited to White House with GiveaRoof 3-Year Plan to End Homelessness
-
Third-ranked Pegula, Medvedev power into US Open third round
-
Trump floats renaming Strait of Hormuz as 'Trump Strait'
-
Davis-Woodhall a doubt for Ultimate Championship after car crash
-
Man City, Chelsea fuel record-breaking Premier League transfer window
-
Third-ranked Pegula powers into US Open third round
-
Balogun rejected Everton move over transfer 'treatment'
-
Uber says laying off 'about 10%' of workforce worldwide
-
Northampton seek 'happy medium' in bid to keep England star Pollock
-
US judge rejects bid to break up Google's ad business
-
US energy secretary in Venezuela to sign Trump's 'biggest' oil deal
-
Rupert Murdoch 'very happy' to be played by Guy Pearce in new film
-
Branagh takes on action role in Apple's Cold War comedy 'Mayday'
-
Wall Street stocks rise despite bond yields, oil rising
-
Lawson fills in again for injured Hadjar at Monza
-
Brennan claims third Vuelta victory in stage 11 sprint
-
England omit Carse from squad for third Test against Pakistan
-
Nepal flood survivors cling to zipline to cross treacherous river
-
Venice festival gets underway with Clooney taking swipe at US government
-
US Treasury issues $1 coin with Trump's face on it
-
DNA tests and funerals in Nepal, a week after deadly floods
-
Fernandez 'didn't hesitate' over record Man City move
-
Iran threatens tougher strategy after US strikes kill 4 at wedding
-
Dutch shift 86 tonnes of gold from US, Canada to UK
-
Chevron unveils deal to double Venezuela venture output in 5 years
-
Nepal floods should mobilise climate action: UN green fund chief
-
Uganda names its oil 'Pearl Sweet' as it prepares for first exports
-
Nvidia boss presses G20 ministers to build AI infrastructure
Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
L.Mason--AMWN